Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)

Pantelis A. Sarafidis, Alexandre Persu, Rajiv Agarwal, Michel Burnier, Peter de Leeuw, Charles Ferro, Jean Michel Halimi, Gunnar Heine, Michel Jadoul, Faical Jarraya, Mehmet Kanbay, Francesca Mallamaci, Patrick B. Mark, Alberto Ortiz, Gianfranco Parati, Roberto Pontremoli, Patrick Rossignol, Luis Ruilope, Patricia van der Niepen, Raymond VanholderMarianne C. Verharr, Andrzej Wiecek, Gregoire Wuerzner, Gérard M. London, Carmine Zoccali

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In patients with end-stage renal disease treated with hemodialysis or peritoneal dialysis, hypertension is very common and often poorly controlled. Blood pressure (BP) recordings obtained before or after hemodialysis display a J-shaped or U-shaped association with cardiovascular events and survival, but this most likely reflects the low accuracy of these measurements and the peculiar hemodynamic setting related with dialysis treatment. Elevated BP by home or ambulatory BP monitoring is clearly associated with shorter survival. Sodium and volume excess is the prominent mechanism of hypertension in dialysis patients, but other pathways, such as arterial stiffness, activation of the renin–angiotensin–aldosterone and sympathetic nervous systems, endothelial dysfunction, sleep apnea and the use of erythropoietin-stimulating agents may also be involved. Nonpharmacologic interventions targeting sodium and volume excess are fundamental for hypertension control in this population. If BP remains elevated after appropriate treatment of sodium-volume excess, the use of antihypertensive agents is necessary. Drug treatment in the dialysis population should take into consideration the patientʼs comorbidities and specific characteristics of each agent, such as dialysability. This document is an overview of the diagnosis, epidemiology, pathogenesis and treatment of hypertension in patients on dialysis, aiming to offer the renal physician practical recommendations based on current knowledge and expert opinion and to highlight areas for future research.

Original languageEnglish (US)
JournalJournal of Hypertension
DOIs
StateAccepted/In press - Feb 2 2017

Fingerprint

Dialysis
Medicine
Hypertension
Transplants
Kidney
Ambulatory Blood Pressure Monitoring
Sodium
Blood Pressure
Renal Dialysis
Vascular Stiffness
Survival
Sympathetic Nervous System
Sleep Apnea Syndromes
Expert Testimony
Peritoneal Dialysis
Therapeutics
Erythropoietin
Antihypertensive Agents
Population
Chronic Kidney Failure

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Hypertension in dialysis patients : a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). / Sarafidis, Pantelis A.; Persu, Alexandre; Agarwal, Rajiv; Burnier, Michel; de Leeuw, Peter; Ferro, Charles; Halimi, Jean Michel; Heine, Gunnar; Jadoul, Michel; Jarraya, Faical; Kanbay, Mehmet; Mallamaci, Francesca; Mark, Patrick B.; Ortiz, Alberto; Parati, Gianfranco; Pontremoli, Roberto; Rossignol, Patrick; Ruilope, Luis; van der Niepen, Patricia; Vanholder, Raymond; Verharr, Marianne C.; Wiecek, Andrzej; Wuerzner, Gregoire; London, Gérard M.; Zoccali, Carmine.

In: Journal of Hypertension, 02.02.2017.

Research output: Contribution to journalArticle

Sarafidis, PA, Persu, A, Agarwal, R, Burnier, M, de Leeuw, P, Ferro, C, Halimi, JM, Heine, G, Jadoul, M, Jarraya, F, Kanbay, M, Mallamaci, F, Mark, PB, Ortiz, A, Parati, G, Pontremoli, R, Rossignol, P, Ruilope, L, van der Niepen, P, Vanholder, R, Verharr, MC, Wiecek, A, Wuerzner, G, London, GM & Zoccali, C 2017, 'Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)', Journal of Hypertension. https://doi.org/10.1097/HJH.0000000000001283
Sarafidis, Pantelis A. ; Persu, Alexandre ; Agarwal, Rajiv ; Burnier, Michel ; de Leeuw, Peter ; Ferro, Charles ; Halimi, Jean Michel ; Heine, Gunnar ; Jadoul, Michel ; Jarraya, Faical ; Kanbay, Mehmet ; Mallamaci, Francesca ; Mark, Patrick B. ; Ortiz, Alberto ; Parati, Gianfranco ; Pontremoli, Roberto ; Rossignol, Patrick ; Ruilope, Luis ; van der Niepen, Patricia ; Vanholder, Raymond ; Verharr, Marianne C. ; Wiecek, Andrzej ; Wuerzner, Gregoire ; London, Gérard M. ; Zoccali, Carmine. / Hypertension in dialysis patients : a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). In: Journal of Hypertension. 2017.
@article{a2679ab82f544f609332fd219dde1e5c,
title = "Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)",
abstract = "In patients with end-stage renal disease treated with hemodialysis or peritoneal dialysis, hypertension is very common and often poorly controlled. Blood pressure (BP) recordings obtained before or after hemodialysis display a J-shaped or U-shaped association with cardiovascular events and survival, but this most likely reflects the low accuracy of these measurements and the peculiar hemodynamic setting related with dialysis treatment. Elevated BP by home or ambulatory BP monitoring is clearly associated with shorter survival. Sodium and volume excess is the prominent mechanism of hypertension in dialysis patients, but other pathways, such as arterial stiffness, activation of the renin–angiotensin–aldosterone and sympathetic nervous systems, endothelial dysfunction, sleep apnea and the use of erythropoietin-stimulating agents may also be involved. Nonpharmacologic interventions targeting sodium and volume excess are fundamental for hypertension control in this population. If BP remains elevated after appropriate treatment of sodium-volume excess, the use of antihypertensive agents is necessary. Drug treatment in the dialysis population should take into consideration the patientʼs comorbidities and specific characteristics of each agent, such as dialysability. This document is an overview of the diagnosis, epidemiology, pathogenesis and treatment of hypertension in patients on dialysis, aiming to offer the renal physician practical recommendations based on current knowledge and expert opinion and to highlight areas for future research.",
author = "Sarafidis, {Pantelis A.} and Alexandre Persu and Rajiv Agarwal and Michel Burnier and {de Leeuw}, Peter and Charles Ferro and Halimi, {Jean Michel} and Gunnar Heine and Michel Jadoul and Faical Jarraya and Mehmet Kanbay and Francesca Mallamaci and Mark, {Patrick B.} and Alberto Ortiz and Gianfranco Parati and Roberto Pontremoli and Patrick Rossignol and Luis Ruilope and {van der Niepen}, Patricia and Raymond Vanholder and Verharr, {Marianne C.} and Andrzej Wiecek and Gregoire Wuerzner and London, {G{\'e}rard M.} and Carmine Zoccali",
year = "2017",
month = "2",
day = "2",
doi = "10.1097/HJH.0000000000001283",
language = "English (US)",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Hypertension in dialysis patients

T2 - a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)

AU - Sarafidis, Pantelis A.

AU - Persu, Alexandre

AU - Agarwal, Rajiv

AU - Burnier, Michel

AU - de Leeuw, Peter

AU - Ferro, Charles

AU - Halimi, Jean Michel

AU - Heine, Gunnar

AU - Jadoul, Michel

AU - Jarraya, Faical

AU - Kanbay, Mehmet

AU - Mallamaci, Francesca

AU - Mark, Patrick B.

AU - Ortiz, Alberto

AU - Parati, Gianfranco

AU - Pontremoli, Roberto

AU - Rossignol, Patrick

AU - Ruilope, Luis

AU - van der Niepen, Patricia

AU - Vanholder, Raymond

AU - Verharr, Marianne C.

AU - Wiecek, Andrzej

AU - Wuerzner, Gregoire

AU - London, Gérard M.

AU - Zoccali, Carmine

PY - 2017/2/2

Y1 - 2017/2/2

N2 - In patients with end-stage renal disease treated with hemodialysis or peritoneal dialysis, hypertension is very common and often poorly controlled. Blood pressure (BP) recordings obtained before or after hemodialysis display a J-shaped or U-shaped association with cardiovascular events and survival, but this most likely reflects the low accuracy of these measurements and the peculiar hemodynamic setting related with dialysis treatment. Elevated BP by home or ambulatory BP monitoring is clearly associated with shorter survival. Sodium and volume excess is the prominent mechanism of hypertension in dialysis patients, but other pathways, such as arterial stiffness, activation of the renin–angiotensin–aldosterone and sympathetic nervous systems, endothelial dysfunction, sleep apnea and the use of erythropoietin-stimulating agents may also be involved. Nonpharmacologic interventions targeting sodium and volume excess are fundamental for hypertension control in this population. If BP remains elevated after appropriate treatment of sodium-volume excess, the use of antihypertensive agents is necessary. Drug treatment in the dialysis population should take into consideration the patientʼs comorbidities and specific characteristics of each agent, such as dialysability. This document is an overview of the diagnosis, epidemiology, pathogenesis and treatment of hypertension in patients on dialysis, aiming to offer the renal physician practical recommendations based on current knowledge and expert opinion and to highlight areas for future research.

AB - In patients with end-stage renal disease treated with hemodialysis or peritoneal dialysis, hypertension is very common and often poorly controlled. Blood pressure (BP) recordings obtained before or after hemodialysis display a J-shaped or U-shaped association with cardiovascular events and survival, but this most likely reflects the low accuracy of these measurements and the peculiar hemodynamic setting related with dialysis treatment. Elevated BP by home or ambulatory BP monitoring is clearly associated with shorter survival. Sodium and volume excess is the prominent mechanism of hypertension in dialysis patients, but other pathways, such as arterial stiffness, activation of the renin–angiotensin–aldosterone and sympathetic nervous systems, endothelial dysfunction, sleep apnea and the use of erythropoietin-stimulating agents may also be involved. Nonpharmacologic interventions targeting sodium and volume excess are fundamental for hypertension control in this population. If BP remains elevated after appropriate treatment of sodium-volume excess, the use of antihypertensive agents is necessary. Drug treatment in the dialysis population should take into consideration the patientʼs comorbidities and specific characteristics of each agent, such as dialysability. This document is an overview of the diagnosis, epidemiology, pathogenesis and treatment of hypertension in patients on dialysis, aiming to offer the renal physician practical recommendations based on current knowledge and expert opinion and to highlight areas for future research.

UR - http://www.scopus.com/inward/record.url?scp=85011665850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011665850&partnerID=8YFLogxK

U2 - 10.1097/HJH.0000000000001283

DO - 10.1097/HJH.0000000000001283

M3 - Article

C2 - 28157814

AN - SCOPUS:85011665850

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

ER -